ST-920
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ST-920, covering 2025-05-25 to 2026-04-14. Get the full timeline:
Most recent: Clinical Trial Update: Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR) [Phase 1, Phase 2]